Century Therapeutics (United States)
company in Philadelphia, United States
IPSC Nasdaq
SEC CIK 1850119
Follow Century Therapeutics (United States)
Weekly email: filings, results
Net income
−$23.5M
+31.9% vs same quarter last year
EPS, diluted
−$0.11
+72.5% vs same quarter last year
Operating cash flow
−$22.2M
+13.1% vs same quarter last year
Operating income
−$25.2M
+30.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $109.2M | −$9.6M |
| FY24 | $6.6M | −$126.6M |
| FY23 | $2.2M | −$136.7M |
| FY22 | $5.2M | −$130.9M |
| FY21 | - | −$95.8M |
| FY20 | - | −$53.6M |
| FY19 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −15.8% | −8.8% |
| FY24 | −2096.5% | −1920.9% |
| FY23 | −6556.9% | −6115.1% |
| FY22 | −2574.2% | −2518.4% |
| FY21 | - | - |
| FY20 | - | - |
| FY19 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$104.7M |
| FY24 | −$110.3M |
| FY23 | −$102.1M |
| FY22 | −$16.6M |
| FY21 | −$134M |
| FY20 | −$51.1M |
| FY19 | - |
- Century Therapeutics (United States)
- Healthcare median
Show the numbers
| Year | Century Therapeutics (United States) | Healthcare median |
|---|---|---|
| FY25 | −8.8% | −30.6% |
| FY24 | −1920.9% | −47% |
| FY23 | −6115.1% | −58% |
| FY22 | −2518.4% | −80.4% |
| FY21 | - | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |